Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort - Takeaways - MDSpire

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort

  • By

  • Vincenzo Mangialardi

  • Giuseppe Macchitella

  • Rita Vitobello

  • Antonella Teofilo

  • Nicola Cavalli

  • Caterina Lapucci

  • Marco Vercellino

  • Elisa Idini

  • Jessica Frau

  • Pietro Iaffaldano

  • Paola Cavalla

  • Matilde M. Inglese

  • Eleonora Cocco

  • Damiano Paolicelli

  • May 31, 2026

  • 0 min

Share

  • 1

    Ofatumumab significantly reduced relapse rates and MRI activity in both treatment-naïve patients and those switching from other therapies.

  • 2

    Disability outcomes remained stable across treatment subgroups, with no significant differences observed during follow-up.

  • 3

    Prior exposure to high-efficacy therapies was identified as the only independent predictor of infection risk while on ofatumumab.

  • 4

    The study utilized a retrospective, multicenter design across four Italian MS centers to assess real-world effectiveness and safety of ofatumumab.

  • 5

    Clinical endpoints included annualized relapse rate, confirmed disability worsening, and no evidence of disease activity, evaluated at 12 months.

Original Source(s)

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort

  • by Vincenzo Mangialardi, Giuseppe Macchitella, Rita Vitobello, Antonella Teofilo, Nicola Cavalli, Caterina Lapucci, Marco Vercellino, Elisa Idini, Jessica Frau, Pietro Iaffaldano, Paola Cavalla, Matilde M. Inglese, Eleonora Cocco, Damiano Paolicelli

  • May 31, 2026

Related Content

Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum

A network meta-analysis of the performance of acupoint stimulation therapy in improving fatigue, neurological function, and activities of daily living in patients with multiple sclerosis

Epitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectives